Get the Stockscreener App
4.78
0.62%
-0.03
Ventyx Biosciences Inc stock is currently priced at $4.78, with a 24-hour trading volume of 422.72K.
It has seen a -0.62% decreased in the last 24 hours and a +27.81% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.85 pivot point. If it approaches the $4.70 support level, significant changes may occur.
Previous Close:
$4.81
Open:
$4.82
24h Volume:
422.72K
Market Cap:
$336.99M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-1.7071
EPS:
-2.8
Net Cash Flow:
$-167.04M
1W Performance:
+9.38%
1M Performance:
+27.81%
6M Performance:
+121.30%
1Y Performance:
-86.13%
1D Range:
$4.68
$5.14
52W Range:
$1.865
$40.58
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
760-593-4832
Address
662 Encinitas Boulevard, Suite 250, Encinitas
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
VENTYX SHAREHOLDER REMINDER: BFA Law Reminds Ventyx Biosciences, Inc. (NASDAQ: VTYX) Shareholders to ... - GlobeNewswire
GlobeNewswire
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Defense World
Jump Financial LLC Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Defense World
VTYX’s Debt-to-Equity Ratio at 0.04: What It Means for Ventyx Biosciences Inc’s Future - The InvestChronicle
The InvestChronicle
Ventyx Biosciences Inc's results are impressive – US Post News - US Post News
US Post News
130749 Shares in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Acquired by Dynamic Technology Lab Private Ltd - Defense World
Defense World
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Ventyx Biosciences Inc (VTYX) Net Income 2024
VTYX net income (TTM) was -$192.96 million for the quarter ending December 31, 2023, a -77.97% decrease year-over-year.
Ventyx Biosciences Inc (VTYX) Cash Flow 2024
VTYX recorded a free cash flow (TTM) of -$167.04 million for the quarter ending December 31, 2023, a -68.64% decrease year-over-year.
Ventyx Biosciences Inc (VTYX) Earnings per Share 2024
VTYX earnings per share (TTM) was -$3.30 for the quarter ending December 31, 2023, a -60.98% decline year-over-year.
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
0.79%
3.50%
Cap:
|
Volume (24h):